Home » Stocks » RUBY

Rubius Therapeutics, Inc. (RUBY)

Stock Price: $10.21 USD 0.21 (2.10%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $10.00 -0.21 (-2.06%) Jan 26, 5:46 PM
Market Cap 826.23M
Revenue (ttm) n/a
Net Income (ttm) -171.66M
Shares Out 80.78M
EPS (ttm) -2.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $10.21
Previous Close $10.00
Change ($) 0.21
Change (%) 2.10%
Day's Open 10.07
Day's Range 10.05 - 10.66
Day's Volume 706,410
52-Week Range 3.74 - 10.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 day ago

Rubius has an interesting science hypothesis, however it failed a first proof of concept trial. It is now running its next one. They have adequate cash for the time being.

GlobeNewsWire - 3 weeks ago

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...

GlobeNewsWire - 2 months ago

Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2  Solid Tumor Clinical Trial

GlobeNewsWire - 2 months ago

RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion In Vitro and In Vivo RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and E...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...

GlobeNewsWire - 2 months ago

RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulatio...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...

The Motley Fool - 4 months ago

These biotechs have a long road ahead, but they just might deliver massive growth.

Other stocks mentioned: JNCE, SRNE
GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...

GlobeNewsWire - 5 months ago

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for  RTX-240 Phase 1/2 Solid Tumor Clinical Trial

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

Seeking Alpha - 6 months ago

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ISEE, ZYNE
GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

GlobeNewsWire - 7 months ago

RTX-321 May Induce Epitope Spreading and Long-Term Tumor Memory RTX-321 May Induce Epitope Spreading and Long-Term Tumor Memory

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to crea...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to crea...

GlobeNewsWire - 8 months ago

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

Seeking Alpha - 10 months ago

Rubius Therapeutics' (RUBY) CEO Pablo Cagnoni on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...

About RUBY

Rubius Therapeutics focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
IPO Date
Jul 18, 2018
CEO
Pablo Cagnoni
Employees
197
Stock Exchange
NASDAQ
Ticker Symbol
RUBY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for RUBY stock is "Buy." The 12-month stock price forecast is 10.29, which is an increase of 0.78% from the latest price.

Price Target
$10.29
(0.78% upside)
Analyst Consensus: Buy